Biodrugs

Papers
(The TQCC of Biodrugs is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Clinical Features and Drug Retention of TNF Inhibitors in Older Patients with Ankylosing Spondylitis: Results from the KOBIO Registry262
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond173
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making94
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor90
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome79
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis66
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis63
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy56
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design51
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery45
Acknowledgement to Referees44
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials42
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?36
CAR-T Cells and the Kidney: Insights from the WHO Safety Database36
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart34
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies33
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202232
Correction to: Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy31
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic31
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?30
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review30
Progress and Challenges in the Treatment of Fabry Disease29
Malaria Vaccines: Progress to Date29
First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data27
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase27
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?26
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer26
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience25
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects25
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series24
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?23
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review23
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options22
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment21
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study20
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout20
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network20
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics19
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight19
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine19
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu18
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study18
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis18
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects17
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 16
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy16
Tolerability and Reactogenicity Profile of mRNA SARS-Cov-2 Vaccines from a Mass Vaccination Campaign in a Tertiary Hospital: Between-Vaccine and Between-Population Prospective Observational Study (Vig16
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa16
HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Heal15
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study15
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review15
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials15
The Use of Biologics for Thyroid Eye Disease15
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics14
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression14
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database14
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis13
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases13
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab13
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria13
Patients’ Perceptions of Biosimilars: A Systematic Review12
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies12
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing12
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context12
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance12
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease12
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine12
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs12
0.26857304573059